Jun. 24 at 4:52 PM
$IBRX Hey
$PFE THINK you may have bet on the wrong asset for 2L NSCLC. 🤷♂️
Check out Anktiva if you want to salvage Sigvotatug vedotin.
Maybe you can do a combo regimen? 🤔
Dr. PSS was right all along. Solid tumor treatments need to both release the brakes on T-cells & TRIGGER the adaptive immune response while at the same time stimulate the the NK cells's innate immune response.
👍
$20-30 LT PT ☘️💎
"Pfizer said Monday that the therapy, an antibody-drug conjugate called sigvotatug vedotin, didn't significantly extend survival compared to a common chemotherapy in a Phase 3 study in people with advanced, non-squamous non-small cell lung cancer. ... Sigvotatug vedotin's study failure is "unlikely to help confidence" in the Seagen deal and could result in another impairment charge, he added. "
https://finance.yahoo.com/healthcare/articles/pfizer-drug-acquired-seagen-deal-120600236.html
